Genopole

Jean-Michel Hayer, as CEO of Genopole, oversees the biocluster's operations including the Genopole Invest vehicle. Investment decisions are made by an internal team drawing on the scientific advisory network within the Genopole campus laboratories. The governance blends public-sector accountability with private investment discipline, given the entity's funding from the French state, regional government, and European programs.

Genopole sources deals almost entirely from within its own ecosystem. The cluster houses approximately 80 biotech startups and 20 academic laboratories, creating a closed-loop pipeline where the investment arm encounters companies at formation, often before they seek external capital. This campus-based model gives Genopole visibility into research programs years before commercial validation.

Genopole is neither a family office nor a traditional venture capital firm. It is a public-private biocluster — a French Groupement d'Intérêt Public — that combines a research campus, business incubator, and direct investment vehicle under one entity. The investment arm, Genopole Invest, deploys seed capital into life sciences startups, but unlike a venture firm it does not raise third-party limited partner capital, and unlike a family office it manages public-sector funds rather than private family wealth.

Genopole executes direct equity investments in early-stage life sciences companies, typically at seed or start-up stage. There is no public evidence that it makes fund commitments to external managers. Its mandate focuses on direct stakes in companies originating from its own research ecosystem in Évry.

Genopole Invest targets seed and early start-up stage companies, often at the point of technology transfer from academic research to commercial venture. It provides the first institutional capital for many of its portfolio companies, bridging the gap between public research grants and Series A venture rounds.

Genopole focuses exclusively on life sciences and biotech — particularly genomics, synthetic biology, gene therapy, and bioinformatics. It does not invest in consumer technology, software, fintech, real estate, or other sectors outside the biological sciences. Its mandate is tied to the research strengths of its campus laboratories.

Genopole's capital derives from public sources rather than private wealth. Funding flows from the French state, the Île-de-France regional government, the European Union's innovation programs, and contributions from academic and industrial partners within the biocluster. There is no single-family wealth origin or private foundation backing the entity.